A Study of the Bruton’xxs Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma | AVESİS

Ondokuz Mayıs Üniversitesi Akademik Veri Yönetim Sistemi

A Study of the Bruton’xxs Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Turgut M., Kelkitli E.

Diğer Uluslararası Fon Programları, 2016 - 2019

Proje Türü: Diğer Uluslararası Fon Programları
Başlama Tarihi: Nisan 2016
Bitiş Tarihi: Haziran 2019